These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 36677847)

  • 1. An Exemestane Derivative, Oxymestane-D1, as a New Multi-Target Steroidal Aromatase Inhibitor for Estrogen Receptor-Positive (ER
    Amaral C; Correia-da-Silva G; Almeida CF; Valente MJ; Varela C; Tavares-da-Silva E; Vinggaard AM; Teixeira N; Roleira FMF
    Molecules; 2023 Jan; 28(2):. PubMed ID: 36677847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of steroidal aromatase inhibitors on sensitive and resistant breast cancer cells: aromatase inhibition and autophagy.
    Amaral C; Varela C; Azevedo M; da Silva ET; Roleira FM; Chen S; Correia-da-Silva G; Teixeira N
    J Steroid Biochem Mol Biol; 2013 May; 135():51-9. PubMed ID: 23318878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of new C6-substituted steroidal aromatase inhibitors in hormone-sensitive breast cancer cells: Cell death mechanisms and modulation of estrogen and androgen receptors.
    Augusto TV; Amaral C; Varela CL; Bernardo F; da Silva ET; Roleira FFM; Costa S; Teixeira N; Correia-da-Silva G
    J Steroid Biochem Mol Biol; 2019 Dec; 195():105486. PubMed ID: 31557516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential clinical benefit of targeting androgen receptor (AR) in estrogen-receptor positive breast cancer cells treated with Exemestane.
    Amaral C; Augusto TV; Almada M; Cunha SC; Correia-da-Silva G; Teixeira N
    Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165661. PubMed ID: 31891807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor efficacy of new 7α-substituted androstanes as aromatase inhibitors in hormone-sensitive and resistant breast cancer cells.
    Amaral C; Varela CL; Maurício J; Sobral AF; Costa SC; Roleira FMF; Tavares-da-Silva EJ; Correia-da-Silva G; Teixeira N
    J Steroid Biochem Mol Biol; 2017 Jul; 171():218-228. PubMed ID: 28396197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a multi-target compound for estrogen receptor-positive (ER
    Almeida CF; Teixeira N; Oliveira A; Augusto TV; Correia-da-Silva G; Ramos MJ; Fernandes PA; Amaral C
    Biochimie; 2021 Feb; 181():65-76. PubMed ID: 33278557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential biological effects of aromatase inhibitors: Apoptosis, autophagy, senescence and modulation of the hormonal status in breast cancer cells.
    Augusto TV; Amaral C; Almeida CF; Teixeira N; Correia-da-Silva G
    Mol Cell Endocrinol; 2021 Nov; 537():111426. PubMed ID: 34391846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines.
    Masri S; Phung S; Wang X; Chen S
    J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):277-82. PubMed ID: 19897035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor.
    Masri S; Phung S; Wang X; Wu X; Yuan YC; Wagman L; Chen S
    Cancer Res; 2008 Jun; 68(12):4910-8. PubMed ID: 18559539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.
    Rechoum Y; Rovito D; Iacopetta D; Barone I; Andò S; Weigel NL; O'Malley BW; Brown PH; Fuqua SA
    Breast Cancer Res Treat; 2014 Oct; 147(3):473-85. PubMed ID: 25178514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
    Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
    Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exemestane metabolites: Synthesis, stereochemical elucidation, biochemical activity and anti-proliferative effects in a hormone-dependent breast cancer cell line.
    Varela CL; Amaral C; Tavares da Silva E; Lopes A; Correia-da-Silva G; Carvalho RA; Costa SC; Roleira FM; Teixeira N
    Eur J Med Chem; 2014 Nov; 87():336-45. PubMed ID: 25277066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications.
    Hanamura T; Hayashi SI
    Breast Cancer; 2018 Jul; 25(4):379-391. PubMed ID: 28389808
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Bezerra PHA; Amaral C; Almeida CF; Correia-da-Silva G; Torqueti MR; Teixeira N
    Molecules; 2023 Jun; 28(13):. PubMed ID: 37446555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer.
    Jayaraman S; Hou X; Kuffel MJ; Suman VJ; Hoskin TL; Reinicke KE; Monroe DG; Kalari KR; Tang X; Zeldenrust MA; Cheng J; Bruinsma ES; Buhrow SA; McGovern RM; Safgren SL; Walden CA; Carter JM; Reid JM; Ingle JN; Ames MM; Hawse JR; Goetz MP
    Breast Cancer Res; 2020 May; 22(1):51. PubMed ID: 32430040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-guided identification of novel dual-targeting estrogen receptor α degraders with aromatase inhibitory activity for the treatment of endocrine-resistant breast cancer.
    Xin L; Min J; Hu H; Li Y; Du C; Xie B; Cheng Y; Deng X; Deng X; Shen K; Huang J; Chen CC; Guo RT; Dong C; Zhou HB
    Eur J Med Chem; 2023 May; 253():115328. PubMed ID: 37037140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen receptor-positive (ER
    Ferreira Almeida C; Oliveira A; João Ramos M; Fernandes PA; Teixeira N; Amaral C
    Biochem Pharmacol; 2020 Jul; 177():113989. PubMed ID: 32330493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
    Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
    Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
    Thomsen KG; Lyng MB; Elias D; Vever H; Knoop AS; Lykkesfeldt AE; Lænkholm AV; Ditzel HJ
    Breast Cancer Res Treat; 2015 Dec; 154(3):483-94. PubMed ID: 26585578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New steroidal aromatase inhibitors: suppression of estrogen-dependent breast cancer cell proliferation and induction of cell death.
    Cepa M; Correia-da-Silva G; da Silva EJ; Roleira FM; Borges M; Teixeira NA
    BMC Cell Biol; 2008 Jul; 9():41. PubMed ID: 18652661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.